Background . Medical management of heart failure with preserved ejection fraction (HFPEF) remains unclear. This analysis was to assess the benefit of ACE-inhibitors (ACEi) and beta blockers (BB) in patients with HFPEF and in heart failure with reduced ejection fraction (HFREF). .Methods . The BACH (Biomarkers in Acute Heart Failure) trial was a prospective, 15-center, international study of 1,641 patients presenting with dyspnea. This is a secondary analysis of the BACH trial. .Results . Patients with a diagnosis of congestive heart failure (CHF) whom were discharged on a BB or an ACEI had improved survival in both HFPEF and HFREF. The propensity score score for being prescribed an ACEi was 0.710 and for a BB was 0.614. A model including all CHF patients and both beta blocker and ACEi, ACEi alone, and BB alone demonstrated the most protective effect with ACEi. .Conclusions . Patients with HFPEF and HFREF both demonstrate improved survival when being discharged on ACEi and BB, with ACEi possibly having more survival benefit. .
Scheda prodotto non validato
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo
|Titolo:||IMPROVED SURVIVAL IN PATIENTS WITH DIASTOLIC HEART FAILURE DISCHARGED ON BETA-BLOCKER AND ACE INHIBITORS|
|Data di pubblicazione:||2013|
|Appartiene alla tipologia:||01a Articolo in rivista|